Neostem Inc., of New York, randomized the first patient in the Intus phase III trial investigating the efficacy of the company's patient-specific targeted cancer immunotherapy candidate, NBS20 (eltrapuldencel-T), in patients with stage III recurrent or stage IV metastatic melanoma.